Argent BioPharma (ASX:RGT) announced a binding framework to license CannEpil globally to Splash Beverage Group. The proposed upfront consideration was forgiveness of US$5.5 million of Mercer debt. Argent said it would retain intellectual property, Manufacturing participation and a Royalty on future sales.

From a Commercial CBD Medicine to an Earlier-Stage Pipeline

CannEpil is a standardised 20:1 cannabidiol-to-tetrahydrocannabinol oral solution developed for drug-resistant epilepsy. In July 2026, Argent announced a global licensing framework with US$5.5 million of upfront consideration structured as forgiveness of approximately US$5.5 million of Mercer Street convertible debt. The company said completion would fully extinguish that secured Facility and release associated security interests. The announcement did not support describing a remaining balance of 3.8 million notes.

What Argent Keeps, and What It Gives Up

Under the announced terms, Splash would hold exclusive global commercial rights, while Argent would retain CannEpil intellectual property and associated regulatory assets. Argent also expected to receive a 15% royalty on net Revenue and continue to participate in manufacturing. The agreement had an initial 20-year term, subject to its terms and any completion requirements.

What the Evidence Means

The structure exchanges a secured Debt obligation for licensing rights rather than a cash receipt. Argent retains potential royalty and manufacturing revenue under the announced terms. The actual debt reduction depends on completion of the transaction.

A Sector Under Pressure to Show a Path to Cash Flow

Argent’s other development programmes require clinical work and funding before any potential commercial sales. The announced debt transaction may change its Balance Sheet if completed, while future expenditure and returns depend on development decisions and licensing terms.

Risks and Milestones Ahead

The transaction’s completion, Splash’s development activities and any future royalty or manufacturing income remain uncertain. The announcement also linked an eventual US regulatory filing to successful clinical trials, so approval or near-term sales should not be assumed.

Readers should look for a completion notice, confirmation of the Mercer facility’s discharge and subsequent CannEpil development updates.